These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27178334)

  • 1. A novel subtype classification and risk of breast cancer by histone modification profiling.
    Chen X; Hu H; He L; Yu X; Liu X; Zhong R; Shu M
    Breast Cancer Res Treat; 2016 Jun; 157(2):267-279. PubMed ID: 27178334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes.
    Xi Y; Shi J; Li W; Tanaka K; Allton KL; Richardson D; Li J; Franco HL; Nagari A; Malladi VS; Coletta LD; Simper MS; Keyomarsi K; Shen J; Bedford MT; Shi X; Barton MC; Kraus WL; Li W; Dent SYR
    BMC Genomics; 2018 Feb; 19(1):150. PubMed ID: 29458327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
    Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
    Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global analysis of H3K4me3 and H3K27me3 profiles in glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor suppressor gene.
    Lin B; Lee H; Yoon JG; Madan A; Wayner E; Tonning S; Hothi P; Schroeder B; Ulasov I; Foltz G; Hood L; Cobbs C
    Oncotarget; 2015 Mar; 6(7):5369-81. PubMed ID: 25749033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.
    Montes de Oca R; Gurard-Levin ZA; Berger F; Rehman H; Martel E; Corpet A; de Koning L; Vassias I; Wilson LO; Meseure D; Reyal F; Savignoni A; Asselain B; Sastre-Garau X; Almouzni G
    Mol Oncol; 2015 Mar; 9(3):657-74. PubMed ID: 25497280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.
    Kaukonen D; Kaukonen R; Polit L; Hennessy BT; Lund R; Madden SF
    BMC Med Genomics; 2020 Jul; 13(1):92. PubMed ID: 32620123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer.
    Chen F; Gao S; Wang F; Ma J; Zhang M; Lv M; Zhou Q; Fu Z; Lu C; Yin H
    Tumour Biol; 2016 Mar; 37(3):3365-70. PubMed ID: 26446459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
    Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
    Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
    Pal B; Chen Y; Bert A; Hu Y; Sheridan JM; Beck T; Shi W; Satterley K; Jamieson P; Goodall GJ; Lindeman GJ; Smyth GK; Visvader JE
    Breast Cancer Res; 2015 Jun; 17(1):85. PubMed ID: 26080807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes.
    Judes G; Dagdemir A; Karsli-Ceppioglu S; Lebert A; Echegut M; Ngollo M; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Epigenomics; 2016 Jul; 8(7):909-24. PubMed ID: 27424567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression patterns associated with p53 status in breast cancer.
    Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM
    BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
    BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of genes and pathways involved in breast cancer subtypes through gene expression meta-analysis.
    Jafarinejad-Farsangi S; Moazzam-Jazi M; Naderi Ghale-Noie Z; Askari N; Miri Karam Z; Mollazadeh S; Hadizadeh M
    Gene; 2022 May; 821():146328. PubMed ID: 35181505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
    Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
    Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncofetal Epigenetic Bivalency in Breast Cancer Cells: H3K4 and H3K27 Tri-Methylation as a Biomarker for Phenotypic Plasticity.
    Messier TL; Boyd JR; Gordon JA; Stein JL; Lian JB; Stein GS
    J Cell Physiol; 2016 Nov; 231(11):2474-81. PubMed ID: 26916849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
    Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
    BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.
    Zhao QY; Lei PJ; Zhang X; Zheng JY; Wang HY; Zhao J; Li YM; Ye M; Li L; Wei G; Wu M
    Clin Epigenetics; 2016; 8():34. PubMed ID: 27034728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
    Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
    Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer.
    Karsli-Ceppioglu S; Dagdemir A; Judes G; Lebert A; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
    Sci Rep; 2017 Jul; 7(1):6597. PubMed ID: 28747748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hyper-activation of transcriptional enhancers in breast cancer.
    Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M
    Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.